Alectinib (Alecensa®)
Dokument
Fact Sheet
Spezifizierung
Lungenkarzinom, nicht-kleinzellig (NSCLC)
» ALK+
» Erstlinie
Stand
Juli 2021
Dies ist die aktuell gültige Version des Dokuments
1Alectinib, NSCLC, ALK+, first line
1 N - number of patients2 RR - remission rate, in %3 PFS - progression-free survival in months5 OS - overall survival in months7 SAE - serious adverse events, CTCAE grade 3/414 results for control, results for new therapy15 hazard ratio for new therapy16 n. s. not significant18 n. r. – median not reached
